Efficacy and Safety of TC011 in Relapsed or Refractory Follicular Lymphoma

This Phase II, multi-center, single-arm, open-label study evaluates the efficacy and safety of TC011, a CD19-targeted CAR-T cell therapy, in adult patients with relapsed or refractory follicular lymphoma (Grade 1, 2, or 3a). The primary endpoint is objective response rate (ORR) assessed by independent review using the Lugano 2014 classification.

NCT Number	NCT07360288
Lead Sponsor	TICAROS Co., Ltd.
Conditions	Follicular Lymphoma (FL)
Enrollment	40 participants
Start Date	2026-03-01
Primary Completion	2028-05-31 (estimated)
Study Completion	2030-02-28 (estimated)
Updated on ClinicalTrials.gov	2026-01-22